Natural Honey in Diabetics

Key findings

• •Adults with type 2 diabetes were randomised to a honey‑supplemented diet or control for 8 weeks.
• •The honey group consumed relatively high daily doses of natural honey.
• •Compared with controls, the honey group showed: modest weight loss, improvement in cholesterol and some lipid markers, no dramatic worsening of fasting blood glucose.
• •Endpoints were soft (metabolic lab values, body weight); no long‑term clinical outcomes were tracked.

Background

• •Standard advice for diabetics is to avoid all sugars, honey included. Bahrami and colleagues asked: When type 2 diabetics consume relatively large amounts of natural honey daily for 8 weeks, what happens to metabolic markers compared with controls?

Methods

• •Participants: adults with type 2 diabetes. Intervention: daily consumption of a specified quantity of natural honey in addition to usual diet. Control: usual diet without added honey (or another carbohydrate source, depending on study arm details). Duration: 8 weeks. Endpoints (soft): fasting blood glucose and possibly HbA1c (depending on reporting), blood lipid profile (total cholesterol, LDL, HDL, triglycerides), body weight and BMI. Randomisation was used; blinding was impossible (honey has obvious taste and appearance).

Results

• •Honey group: lost a small amount of weight on average, showed improvements in total cholesterol and some lipid fractions, did not experience sharp deterioration in fasting glucose; some markers improved or remained stable. Control group: showed less favourable changes or remained largely unchanged.

Interpretation

• •For WorthDay, S06 suggests that: in the short term, natural honey may behave differently from refined sugar in diabetics, honey may have neutral or even positive effects on some metabolic markers at the doses used. But: the trial is only 8 weeks, no hard endpoints (clinical events, complications) were measured, no proper null control (e.g. matching calorie reduction) exists. Therefore, S06 is rated 🟠 low evidence quality: interesting and provocative, but far from definitive.

Limitations

• •Short duration; cannot address long‑term diabetic complications or organ damage.
• •Endpoints limited to lab values and weight; no direct morbidity/mortality data.
• •Participants and staff were unblinded; expectations and lifestyle co‑changes could influence results.
• •Small sample size; statistical power is limited.
• •The specific type and quality of honey may not represent all commercial honey products.

WorthDay perspective

• •S06 supports WorthDay's position that not all sugars are equal, and that whole foods like raw honey deserve to be distinguished from industrial sugar.
• •WorthDay can say: "A small 8‑week randomised trial in diabetics found that high daily intake of natural honey improved some metabolic markers instead of worsening them. This is low‑quality evidence but suggests that natural honey is not metabolically identical to refined sugar."
• •In Foodlovers and Health content: you can frame honey as a possible replacement for refined sugar in small, conscious amounts, encourage users to observe their own energy, appetite and (where relevant) blood sugar responses.
• •The Science Lab entry should emphasise that: this is not a licence for unlimited honey, evidence is limited and short‑term, users should treat this as a hypothesis to test in their own context, not as a medical recommendation.

Notes

Short-term randomised trial in type 2 diabetics (Bahrami et al. 2009): daily natural honey added to usual diet vs control, 8 weeks. Soft endpoints only: body weight, blood lipids, fasting glucose. Honey group showed modest weight loss, improved cholesterol/lipid fractions and no dramatic glucose deterioration; no hard clinical outcomes. Short duration, unblinded, small sample, no proper isocaloric null control. Low evidence (🟠).